Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/20365Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Filippatos, T. | en |
| dc.contributor.author | Milionis, H. J. | en |
| dc.date.accessioned | 2015-11-24T19:06:40Z | - |
| dc.date.available | 2015-11-24T19:06:40Z | - |
| dc.identifier.issn | 1744-7658 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/20365 | - |
| dc.rights | Default Licence | - |
| dc.subject | Angiography | en |
| dc.subject | Clinical Trials as Topic | en |
| dc.subject | Drug Interactions | en |
| dc.subject | Drug Therapy, Combination | en |
| dc.subject | Fenofibrate/adverse effects/*analogs & | en |
| dc.subject | derivatives/pharmacokinetics/pharmacology/*therapeutic use | en |
| dc.subject | Fluorobenzenes/therapeutic use | en |
| dc.subject | Humans | en |
| dc.subject | Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use | en |
| dc.subject | Hyperlipidemias/*drug therapy | en |
| dc.subject | Hypolipidemic Agents/*therapeutic use | en |
| dc.subject | Lipids/blood | en |
| dc.subject | Pyrimidines/therapeutic use | en |
| dc.subject | Sulfonamides/therapeutic use | en |
| dc.title | Treatment of hyperlipidaemia with fenofibrate and related fibrates | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.primary | 10.1517/13543784.17.10.1599 | - |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/18808320 | - |
| heal.identifier.secondary | http://informahealthcare.com/doi/abs/10.1517/13543784.17.10.1599 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2008 | - |
| heal.abstract | BACKGROUND: Fenofibrate is the most widely used fibrate. Its efficacy and tolerability in the treatment of hypertriglyceridaemia and combined hyperlipidaemia have been demonstrated in several clinical trials. OBJECTIVE: To review the pharmacology, lipid-lowering and extra-lipid effects of fenofibrate and to preview ABT-335, an investigational new fenofibric acid molecule. RESULTS: The effects of fenofibrate are mediated through the active metabolite fenofibric acid, and are described in detail in the paper. ABT-335 is a salt of fenofibric acid and, unlike fenofibrate, does not require first pass metabolism to the active moiety. ABT-335 is being developed for combination use with statins, and has recently completed three large Phase III randomised controlled trials in which the efficacy and safety of ABT-335 in combination with the three most commonly prescribed statins, atorvastatin, simvastatin and rosuvastatin, was evaluated in patients with mixed dyslipidaemia. CONCLUSION: ABT-335 in combination with statins may provide a safe and efficacious treatment modality that enables achievement of several therapeutic goals in patients with mixed dyslipidaemia who have high cardiovascular risk. | en |
| heal.journalName | Expert Opin Investig Drugs | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
There are no files associated with this item.
This item is licensed under a Creative Commons License
